Resources Management Corp CT ADV purchased a new stake in Gilead Sciences, Inc. (NASDAQ:GILD) in the 3rd quarter, HoldingsChannel.com reports. The firm purchased 58,856 shares of the biopharmaceutical company’s stock, valued at approximately $3,730,000.
Other large investors have also bought and sold shares of the company. FNY Investment Advisers LLC purchased a new stake in Gilead Sciences in the 2nd quarter valued at $72,000. Brookstone Capital Management purchased a new position in Gilead Sciences during the 2nd quarter worth $2,331,000. Ballentine Partners LLC boosted its holdings in Gilead Sciences by 8.0% during the 2nd quarter. Ballentine Partners LLC now owns 5,373 shares of the biopharmaceutical company’s stock worth $363,000 after acquiring an additional 400 shares during the last quarter. Putnam FL Investment Management Co. boosted its holdings in Gilead Sciences by 6.0% during the 2nd quarter. Putnam FL Investment Management Co. now owns 6,125 shares of the biopharmaceutical company’s stock worth $414,000 after acquiring an additional 346 shares during the last quarter. Finally, Steward Partners Investment Advisory LLC grew its stake in shares of Gilead Sciences by 29.9% in the 2nd quarter. Steward Partners Investment Advisory LLC now owns 38,520 shares of the biopharmaceutical company’s stock worth $2,602,000 after acquiring an additional 8,865 shares in the last quarter. Institutional investors and hedge funds own 79.37% of the company’s stock.
A number of research analysts recently weighed in on GILD shares. BidaskClub raised shares of Gilead Sciences from a “sell” rating to a “hold” rating in a research report on Tuesday, October 15th. ValuEngine upgraded shares of Gilead Sciences from a “sell” rating to a “hold” rating in a report on Wednesday, October 2nd. Wells Fargo & Co set a $81.00 price objective on shares of Gilead Sciences and gave the stock a “buy” rating in a research report on Friday, October 25th. Mizuho set a $81.00 price objective on shares of Gilead Sciences and gave the company a “buy” rating in a research note on Tuesday, October 15th. Finally, Robert W. Baird set a $76.00 target price on shares of Gilead Sciences and gave the stock a “hold” rating in a research report on Friday, October 25th. One research analyst has rated the stock with a sell rating, eleven have assigned a hold rating, fifteen have assigned a buy rating and one has given a strong buy rating to the company. Gilead Sciences currently has a consensus rating of “Buy” and a consensus price target of $79.09.
Shares of NASDAQ GILD traded up $0.68 during trading on Wednesday, reaching $66.75. 5,082,039 shares of the stock traded hands, compared to its average volume of 5,563,803. Gilead Sciences, Inc. has a 52-week low of $60.32 and a 52-week high of $72.63. The company has a debt-to-equity ratio of 1.11, a current ratio of 2.96 and a quick ratio of 2.87. The company has a 50-day moving average of $65.12 and a 200-day moving average of $65.32. The stock has a market capitalization of $84.45 billion, a P/E ratio of 10.85, a price-to-earnings-growth ratio of 3.58 and a beta of 1.14.
Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Thursday, October 24th. The biopharmaceutical company reported $1.75 earnings per share for the quarter, topping the consensus estimate of $1.74 by $0.01. Gilead Sciences had a return on equity of 37.50% and a net margin of 12.04%. The company had revenue of $5.60 billion during the quarter, compared to the consensus estimate of $5.61 billion. During the same quarter in the prior year, the company earned $1.84 EPS. The firm’s quarterly revenue was up .1% compared to the same quarter last year. Analysts expect that Gilead Sciences, Inc. will post 6.64 earnings per share for the current fiscal year.
The firm also recently disclosed a quarterly dividend, which will be paid on Monday, December 30th. Shareholders of record on Friday, December 13th will be issued a dividend of $0.63 per share. This represents a $2.52 annualized dividend and a yield of 3.78%. The ex-dividend date is Thursday, December 12th. Gilead Sciences’s dividend payout ratio (DPR) is presently 40.98%.
About Gilead Sciences
Gilead Sciences, Inc, a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, and Truvada for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, and Viread products for treating liver diseases.
Featured Story: What is the NASDAQ Stock Market?
Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.